​

SCYNEXIS Stock (NASDAQ:SCYX)

ForecastRevenueOwnershipFinancialsChart
SCYNEXIS by TradingView

Previous Close

$3.57

52W Range

$3.53 - $10.48

50D Avg

$4.54

200D Avg

$5.77

Market Cap

$22.83M

Avg Vol (3M)

$70.30K

Beta

1.10

Div Yield

-

SCYX Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

18

IPO Date

May 02, 2014

Website

SCYX Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Product$1.44M$1.04M-
License and Service$19.16M$3.75M$139.10M

Fiscal year ends in Dec 25 | Currency in USD

SCYX Financial Summary

Dec 25Dec 24Dec 23
Revenue$20.60M$3.75M$140.14M
Operating Income$-16.07M$-37.12M$72.67M
Net Income$-8.61M$-21.29M$67.04M
EBITDA$-16.07M$-18.58M$70.89M
Basic EPS$-0.17$-0.44$1.40
Diluted EPS$-0.17$-0.44$1.39

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q3 22Nov 09, 22 | 8:30 AM
Q2 22Aug 15, 22 | 8:30 AM
Q1 22May 12, 22 | 8:30 AM

Peer Comparison

TickerCompany
XCURExicure, Inc.
KLTOKlotho Neurosciences, Inc.
CLGNCollPlant Biotechnologies Ltd.
NRSNNeuroSense Therapeutics Ltd.
COSMCosmos Health Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
NXLNexalin Technology, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
TLPHTalphera, Inc.